Neville Rodie & Shaw Inc Aadi Bioscience, Inc. Transaction History
Neville Rodie & Shaw Inc
- $1.37 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding AADI
# of Institutions
57Shares Held
15.6MCall Options Held
15KPut Options Held
3.1K-
Avoro Capital Advisors LLC New York, NY2.85MShares$8.18 Million0.13% of portfolio
-
Qvt Financial LP New York, NY2.31MShares$6.64 Million0.72% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.1MShares$6.03 Million4.12% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$5.31 Million8.31% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.15MShares$3.29 Million1.96% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $60.3M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...